Elacestrant (Korserdu, Menarini Stemline) is indicated for 'the treatment of postmenopausal women, and men, with estrogen receptor (ER)-positive, HER2-negative, locally advanced or metastatic breast ...

The appraisal committee has prepared final draft guidance (FDG) on elacestrant for treating oestrogen receptor-positive, HER2-negative advanced breast cancer with an ESR1 mutation after endocrine ...